| 臺大學術典藏 |
2022-02-22T05:34:12Z |
Hepatitis C virus core antigen is cost-effective in community-based screening of active hepatitis C infection in Taiwan
|
Wang J.-H.; CHIEN-HUNG CHEN; Chang C.-M.; Feng W.-C.; Lee C.-Y.; Lu S.-N. |
| 臺大學術典藏 |
2022-02-22T05:34:11Z |
Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan
|
Chiu W.-N.; Hung C.-H.; Lu S.-N.; Chen M.-Y.; Tung S.-Y.; Wei K.-L.; Lu C.-K.; CHIEN-HUNG CHEN; Hu T.-H.; Hu J.-H.; Chen W.-M.; Chang T.-S. |
| 臺大學術典藏 |
2022-02-22T05:34:11Z |
Liver stiffness-based score at sustained virologic response predicts liver-related complications after eradication of hepatitis C virus
|
Kuo Y.-H.; Kee K.-M.; Hung C.-H.; Lu S.-N.; Hu T.-H.; CHIEN-HUNG CHEN; Wang J.-H. |
| 臺大學術典藏 |
2022-02-22T05:34:10Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; CHIEN-HUNG CHEN; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2022-02-22T05:34:08Z |
How may ramucirumab help improve treatment outcome for patients with gastrointestinal cancers?
|
Chen M.-H.; Lu S.-N.; CHIEN-HUNG CHEN; Lin P.-C.; Jiang J.-K.; D’yachkova Y.; Lukanowski M.; Cheng R.; Chen L.-T. |
| 臺大學術典藏 |
2022-02-22T05:34:08Z |
Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
|
Kuo Y.-H.; Lu S.-N.; Chen Y.-Y.; Kee K.-M.; Yen Y.-H.; Hung C.-H.; Hu T.-H.; CHIEN-HUNG CHEN; Wang J.-H. |
| 臺大學術典藏 |
2022-02-22T05:34:07Z |
Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis (Front. Oncol., (2021), 11, (737767), 10.3389/fonc.2021.737767)
|
Kuo Y.-H.; Lu S.-N.; Chen Y.-Y.; Kee K.-M.; Yen Y.-H.; Hung C.-H.; Hu T.-H.; CHIEN-HUNG CHEN; Wang J.-H. |
| 臺大學術典藏 |
2022-02-18T08:26:09Z |
Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: A community-based long-term prospective study
|
Lee M.-H.; Yang H.-I.; Lu S.-N.; Jen C.-L.; You S.-L.; Wang L.-Y.; Wang C.-H.; Chen W.J.; Chen C.-J.; Hsieh C.Y.; Lee H.S.; Yang P.M.; Chen C.H.; Chen J.D.; Huang S.P.; Jan C.F.; Chen T.H.H.; Sun C.A.; Wu M.H.; Chen S.Y.; Chu K.E.; Ho S.C.; Lu T.G.; Wu W.P.; Ou T.Y.; Lin C.G.; Shih K.C.; Chung W.S.; Li C.; CHIEH-CHANG CHEN; How W.C. |
| 臺大學術典藏 |
2022-02-18T08:26:03Z |
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients
|
Lee M.-H.; Huang C.-F.; Lai H.-C.; Lin C.-Y.; Dai C.-Y.; Liu C.-J.; Wang J.-H.; Huang J.-F.; Su W.-P.; Yang H.-C.; Kee K.-M.; Yeh M.-L.; Chuang P.-H.; Hsu S.-J.; Huang C.-I.; Kao J.-T.; CHIEH-CHANG CHEN; Chen S.-H.; Jeng W.-J.; Yang H.-I.; Yuan Y.; Lu S.-N.; Sheen I.-S.; Liu C.-H.; Peng C.-Y.; Kao J.-H.; Yu M.-L.; Chuang W.-L.; Chen C.-J. |
| 臺大學術典藏 |
2022-01-25T05:10:33Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; CHI-LING CHEN; Kao J.-H.; Lai M.-Y.; Liu C.-H.; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Chen P.-J.; Liu C.-J.; Chen D.-S. |
| 臺大學術典藏 |
2022-01-25T05:07:22Z |
Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up
|
Yu M.-L.; Lee C.-M.; CHI-LING CHEN; Chuang W.-L.; Lu S.-N.; Liu C.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Kao J.-H.; Su W.-W.; Lin C.-L.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Liu C.-J. |
| 臺大學術典藏 |
2022-01-25T03:25:21Z |
Plasma adipokines and risk of hepatocellular carcinoma in chronic hepatitis B virus-infected carriers: A prospective study in Taiwan
|
CHI-LING CHEN; Yang W.-S.; Yang H.-I.; Chen C.-F.; You S.-L.; Wang L.-Y.; Lu S.-N.; Liu C.-J.; Kao J.-H.; Chen P.-J.; Chen D.-S.; Chen C.-J. |
| 臺大學術典藏 |
2022-01-25T03:25:00Z |
Secular Trends and Geographic Maps of Hepatitis C Virus Infection among 4 Million Blood Donors in Taiwan from 1999 to 2017
|
Chen Y.-Y.; CHI-LING CHEN; Chen J.-W.; Hsu N.-T.; Wei S.-T.; Hou S.-M.; Lu S.-N.; Chen P.-J. |
| 臺大學術典藏 |
2022-01-24T09:31:58Z |
Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: Long-term predictors from a community-based cohort study
|
Lee M.-H.; Yang H.-I.; Lu S.-N.; Jen C.-L.; Yeh S.-H.; CHUN-JEN LIU; Chen P.-J.; You S.-L.; Wang L.-Y.; Chen W.J.; Chen C.-J. |
| 臺大學術典藏 |
2022-01-24T09:31:58Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; Chen C.-L.; Kao J.-H.; Lai M.-Y.; Liu C.-H.; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Chen P.-J.; CHUN-JEN LIU; Chen D.-S. |
| 臺大學術典藏 |
2022-01-24T09:31:57Z |
Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses
|
Yeh M.-L.; Hung C.-H.; Huang J.-F.; CHUN-JEN LIU; Lee C.-M.; Dai C.-Y.; Wang J.-H.; Lin Z.-Y.; Lu S.-N.; Hu T.-H.; Yu M.-L.; Kao J.-H.; Chuang W.-L.; Chen P.-J.; Chen D.-S. |
| 臺大學術典藏 |
2022-01-24T09:31:55Z |
Community and personal risk factors for hepatitis C virus infection: A survey of 23 820 residents in Taiwan in 1991-2
|
Lee M.-H.; Yang H.-I.; Jen C.-L.; Lu S.-N.; Yeh S.-H.; CHUN-JEN LIU; You S.-L.; Sun C.-A.; Wang L.-Y.; Chen W.J.; Chen C.-J. |
| 臺大學術典藏 |
2022-01-24T09:31:47Z |
Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up
|
Yu M.-L.; Lee C.-M.; Chen C.-L.; Chuang W.-L.; Lu S.-N.; Liu C.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Kao J.-H.; Su W.-W.; Lin C.-L.; Yang H.-C.; Chen P.-J.; Chen D.-S.; CHUN-JEN LIU |
| 臺大學術典藏 |
2022-01-24T09:31:40Z |
Plasma adipokines and risk of hepatocellular carcinoma in chronic hepatitis B virus-infected carriers: A prospective study in Taiwan
|
Chen C.-L.; Yang W.-S.; Yang H.-I.; Chen C.-F.; You S.-L.; Wang L.-Y.; Lu S.-N.; CHUN-JEN LIU; Kao J.-H.; Chen P.-J.; Chen D.-S.; Chen C.-J. |
| 臺大學術典藏 |
2022-01-24T09:31:23Z |
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients
|
Lee M.-H.; Huang C.-F.; Lai H.-C.; Lin C.-Y.; Dai C.-Y.; CHUN-JEN LIU; Wang J.-H.; Huang J.-F.; Su W.-P.; Yang H.-C.; Kee K.-M.; Yeh M.-L.; Chuang P.-H.; Hsu S.-J.; Huang C.-I.; Kao J.-T.; Chen C.-C.; Chen S.-H.; Jeng W.-J.; Yang H.-I.; Yuan Y.; Lu S.-N.; Sheen I.-S.; Liu C.-H.; Peng C.-Y.; Kao J.-H.; Yu M.-L.; Chuang W.-L.; Chen C.-J. |
| 臺大學術典藏 |
2022-01-24T09:31:17Z |
Taiwan consensus statement on the management of chronic hepatitis B
|
Chien R.-N.; Kao J.-H.; Peng C.-Y.; Chen C.-H.; CHUN-JEN LIU; Huang Y.-H.; Hu T.-H.; Yang H.-I.; Lu S.-N.; Ni Y.-H.; Chuang W.-L.; Lee C.-M.; Wu J.-C.; Chen P.-J.; Liaw Y.-F. |
| 臺大學術典藏 |
2022-01-24T09:30:58Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; CHUN-JEN LIU; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2022-01-24T06:05:35Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; CHIUN HSU; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2021-09-04T06:12:14Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; Chen C.-L.; JIA-HORNG KAO; Lai M.-Y.; Liu C.-H.; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Chen P.-J.; Liu C.-J.; Chen D.-S. |
| 臺大學術典藏 |
2021-09-04T06:12:12Z |
Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses
|
Yeh M.-L.; Hung C.-H.; Huang J.-F.; Liu C.-J.; Lee C.-M.; Dai C.-Y.; Wang J.-H.; Lin Z.-Y.; Lu S.-N.; Hu T.-H.; Yu M.-L.; JIA-HORNG KAO; Chuang W.-L.; Chen P.-J.; Chen D.-S. |
| 臺大學術典藏 |
2021-09-04T06:11:51Z |
Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up
|
Yu M.-L.; Lee C.-M.; Chen C.-L.; Chuang W.-L.; Lu S.-N.; Liu C.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; JIA-HORNG KAO; Su W.-W.; Lin C.-L.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Liu C.-J. |
| 臺大學術典藏 |
2021-09-04T06:11:40Z |
Plasma adipokines and risk of hepatocellular carcinoma in chronic hepatitis B virus-infected carriers: A prospective study in Taiwan
|
Chen C.-L.; Yang W.-S.; Yang H.-I.; Chen C.-F.; You S.-L.; Wang L.-Y.; Lu S.-N.; Liu C.-J.; JIA-HORNG KAO; Chen P.-J.; Chen D.-S.; Chen C.-J. |
| 臺大學術典藏 |
2021-09-04T06:11:26Z |
Predicting hepatitis B virus (HBV) surface antigen seroclearance in HBV e antigen-negative patients with chronic hepatitis B: External validation of a scoring system
|
Liu J.; Tseng T.-C.; Yang H.-I.; Lee M.-H.; Batrla-Utermann R.; Jen C.-L.; Lu S.-N.; Wang L.-Y.; You S.-L.; Chen P.-J.; Chen C.-J.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:10:54Z |
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients
|
Lee M.-H.; Huang C.-F.; Lai H.-C.; Lin C.-Y.; Dai C.-Y.; Liu C.-J.; Wang J.-H.; Huang J.-F.; Su W.-P.; Yang H.-C.; Kee K.-M.; Yeh M.-L.; Chuang P.-H.; Hsu S.-J.; Huang C.-I.; JIA-HORNG KAO; Chen C.-C.; Chen S.-H.; Jeng W.-J.; Yang H.-I.; Yuan Y.; Lu S.-N.; Sheen I.-S.; Liu C.-H.; Peng C.-Y.; JIA-HORNG KAO; Yu M.-L.; Chuang W.-L.; Chen C.-J. |
| 臺大學術典藏 |
2021-09-04T05:16:57Z |
Taiwan consensus statement on the management of chronic hepatitis B
|
Chien R.-N.; JIA-HORNG KAO; Peng C.-Y.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Hu T.-H.; Yang H.-I.; Lu S.-N.; Ni Y.-H.; Chuang W.-L.; Lee C.-M.; Wu J.-C.; Chen P.-J.; Liaw Y.-F. |
| 臺大學術典藏 |
2021-08-31T06:29:29Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; Chen C.-H.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; ANN-LII CHENG; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2021-08-31T06:29:18Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen L.-T.; Martinelli E.; ANN-LII CHENG; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Hsu C.; Shen Y.-C.; Tabernero J.; Yen Y.; Hsu C.-H.; Yoshino T.; Douillard J.-Y. |
| 臺大學術典藏 |
2021-08-03T07:10:53Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
YU-YUN SHAO; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2021-07-03T03:35:45Z |
Hepatitis B e antigen and the risk of hepatocellular carcinoma
|
Yang H.-I.; Lu S.-N.; Liaw Y.-F.; You S.-L.; Sun C.-A.; Wang L.-Y.; Hsiao C.K.; PEI-JER CHEN; Chen D.-S.; Chen C.-J. |
| 臺大學術典藏 |
2021-07-03T03:35:04Z |
Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma
|
Yang H.-I.; Yeh S.-H.; PEI-JER CHEN; Iloeje U.H.; Jen C.-L.; Su J.; Wang L.-Y.; Lu S.-N.; You S.-L.; Chen D.-S.; Liaw Y.-F.; Chen C.-J. |
| 臺大學術典藏 |
2021-07-03T03:34:42Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; Chen C.-L.; Kao J.-H.; Lai M.-Y.; Liu C.-H.; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; PEI-JER CHEN; Liu C.-J.; Chen D.-S. |
| 臺大學術典藏 |
2021-07-03T03:34:41Z |
Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: Long-term predictors from a community-based cohort study
|
Lee M.-H.; Yang H.-I.; Lu S.-N.; Jen C.-L.; Yeh S.-H.; Liu C.-J.; PEI-JER CHEN; You S.-L.; Wang L.-Y.; Chen W.J.; Chen C.-J. |
| 臺大學術典藏 |
2021-07-03T03:34:41Z |
A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients
|
Yang T.-S.; Lu S.-N.; Chao Y.; Sheen I.-S.; Lin C.-C.; Wang T.-E.; Chen S.-C.; Wang J.-H.; Liao L.-Y.; Thomson J.A.; Wang-Peng J.; PEI-JER CHEN; Chen L.-T. |
| 臺大學術典藏 |
2021-07-03T03:34:39Z |
Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses
|
Yeh M.-L.; Hung C.-H.; Huang J.-F.; Liu C.-J.; Lee C.-M.; Dai C.-Y.; Wang J.-H.; Lin Z.-Y.; Lu S.-N.; Hu T.-H.; Yu M.-L.; Kao J.-H.; Chuang W.-L.; PEI-JER CHEN; Chen D.-S. |
| 臺大學術典藏 |
2021-07-03T03:34:23Z |
Report from a Viral Hepatitis Policy Forum on implementing the WHO framework for global action on viral hepatitis in North Asia
|
Chen D.-S.; Locarnini S.; Wait S.; Bae S.-H.; PEI-JER CHEN; Fung J.Y.Y.; Kim H.S.; Lu S.-N.; Sung J.; Tanaka J.; Wakita T.; Ward J.; Wallace J. |
| 臺大學術典藏 |
2021-07-03T03:34:20Z |
Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up
|
Yu M.-L.; Lee C.-M.; Chen C.-L.; Chuang W.-L.; Lu S.-N.; Liu C.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Kao J.-H.; Su W.-W.; Lin C.-L.; Yang H.-C.; PEI-JER CHEN; Chen D.-S.; Liu C.-J. |
| 臺大學術典藏 |
2021-07-03T03:34:09Z |
Plasma adipokines and risk of hepatocellular carcinoma in chronic hepatitis B virus-infected carriers: A prospective study in Taiwan
|
Chen C.-L.; Yang W.-S.; Yang H.-I.; Chen C.-F.; You S.-L.; Wang L.-Y.; Lu S.-N.; Liu C.-J.; Kao J.-H.; PEI-JER CHEN; Chen D.-S.; Chen C.-J. |
| 臺大學術典藏 |
2021-07-03T03:34:08Z |
Erratum: Report from a Viral Hepatitis Policy Forum on implementing the WHO framework for global action on viral hepatitis in North Asia (Journal of Hepatology (2013) 59 (1073-1080))
|
Chen D.-S.; Locarnini S.; Wait S.; Bae S.-H.; PEI-JER CHEN; Fung J.Y.Y.; Kim H.S.; Lu S.-N.; Sung J.; Tanaka J.; Wakita T.; Ward J.; Wallace J. |
| 臺大學術典藏 |
2021-07-03T03:34:06Z |
Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma
|
Liu J.; Yang H.-I.; Lee M.-H.; Lu S.-N.; Jen C.-L.; Batrla-Utermann R.; Wang L.-Y.; You S.-L.; Hsiao C.K.; PEI-JER CHEN; Chen C.-J. |
| 臺大學術典藏 |
2021-07-03T03:34:01Z |
Predicting hepatitis B virus (HBV) surface antigen seroclearance in HBV e antigen-negative patients with chronic hepatitis B: External validation of a scoring system
|
Liu J.; Tseng T.-C.; Yang H.-I.; Lee M.-H.; Batrla-Utermann R.; Jen C.-L.; Lu S.-N.; Wang L.-Y.; You S.-L.; PEI-JER CHEN; Chen C.-J.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:33:35Z |
Level of Hepatitis B (HB) Core Antibody Associates With Seroclearance of HBV DNA and HB Surface Antigen in HB e Antigen-Seronegative Patients
|
Hu H.-H.;Liu J.;Chang C.-L.;Jen C.-L.;Lee M.-H.;Lu S.-N.;Wang L.-Y.;Quan Y.;Xia N.-S.;Chen C.-J.;Pei-Jer Chen;Yang H.-I.; Hu H.-H.; Liu J.; Chang C.-L.; Jen C.-L.; Lee M.-H.; Lu S.-N.; Wang L.-Y.; Quan Y.; Xia N.-S.; Chen C.-J.; PEI-JER CHEN; Yang H.-I. |
| 臺大學術典藏 |
2021-07-03T03:33:35Z |
Taiwan consensus statement on the management of chronic hepatitis B
|
Chien R.-N.;Kao J.-H.;Peng C.-Y.;Chen C.-H.;Liu C.-J.;Huang Y.-H.;Hu T.-H.;Yang H.-I.;Lu S.-N.;Ni Y.-H.;Chuang W.-L.;Lee C.-M.;Wu J.-C.;Pei-Jer Chen;Liaw Y.-F.; Chien R.-N.; Kao J.-H.; Peng C.-Y.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Hu T.-H.; Yang H.-I.; Lu S.-N.; Ni Y.-H.; Chuang W.-L.; Lee C.-M.; Wu J.-C.; PEI-JER CHEN; Liaw Y.-F. |
| 臺大學術典藏 |
2021-07-03T03:33:32Z |
Association Between High Levels of Hepatitis B Core Antibody and Seroclearance of Hepatitis B e Antigen in Individuals With Chronic Hepatitis B Virus Infection
|
Liu J.;Hu H.-H.;Chang C.-L.;Jen C.-L.;Lee M.-H.;Lu S.-N.;Wang L.-Y.;Yuan Q.;Xia N.-S.;Sugiyama M.;Nishida N.;Mizokami M.;Chen C.-J.;Pei-Jer Chen;Yang H.-I.; Liu J.; Hu H.-H.; Chang C.-L.; Jen C.-L.; Lee M.-H.; Lu S.-N.; Wang L.-Y.; Yuan Q.; Xia N.-S.; Sugiyama M.; Nishida N.; Mizokami M.; Chen C.-J.; PEI-JER CHEN; Yang H.-I. |
| 臺大學術典藏 |
2021-07-03T03:33:19Z |
Ropeginterferon alfa-2b every 2?weeks as a novel pegylated interferon for patients with chronic hepatitis B
|
Huang Y.-W.; Hsu C.-W.; Lu S.-N.; Yu M.-L.; Su C.-W.; Su W.-W.; Chien R.-N.; Hsu C.-S.; Hsu S.-J.; Lai H.-C.; Qin A.; Tseng K.-C.; PEI-JER CHEN |
| 臺大學術典藏 |
2021-07-02T02:35:35Z |
Plasma adipokines and risk of hepatocellular carcinoma in chronic hepatitis B virus-infected carriers: A prospective study in Taiwan
|
Chen C.-L.; WEI-SHIUNG YANG; Yang H.-I.; Chen C.-F.; You S.-L.; Wang L.-Y.; Lu S.-N.; Liu C.-J.; Kao J.-H.; Chen P.-J.; Chen D.-S.; Chen C.-J. |
